Nature子刊:杨红波团队重要发现GATA3变异,可能增加儿童白血病风险

2022-03-25 复旦大学附属妇产科医院 网络

每一个人类个体中都存在约一百万个的碱基差异,这些遗传变异是否会导致个体对疾病的易感性呢?

近日,我院杨红波研究员在《Nature Genetics》发表重要研究成果:GATA3的遗传性非编码变异通过三维染色质构象改变增加儿童急性淋巴细胞白血病的风险。

每一个人类个体中都存在约一百万个的碱基差异,这些遗传变异是否会导致个体对疾病的易感性呢?近日,复旦大学附属妇产科医院、复旦大学生殖与发育研究院的杨红波研究员与国家儿童医学中心上海儿童医学中心的张辉医生,联合来自美国St. Jude儿童医院的杨俊教授和西北大学Feinberg医学院的岳峰教授团队合作于Nature Genetics期刊发文“Noncoding genetic variation in GATA3 increases acute lymphoblastic leukemia risk through local and global changes in chromatin conformation”,揭示了GATA3基因座的遗传性非编码变异通过影响染色质的三维构象,从而改变细胞信号转导通路增加儿童急性淋巴细胞白血病风险的可能机制。

该研究整合了5008名急性淋巴细胞白血病患儿的靶向测序结果,发现位于GATA3第3个内含子中的rs3824662单核苷酸变异,在Ph-like ALL中呈现极强的关联性,并且从中发现rs3824662风险等位基因A具有较高的增强子转录活性,能上调GATA3表达,而GATA3的表达增加进一步诱导Ph-like ALL相关基因CRLF2高表达,导致三维基因组构象改变,激活CRLF2-JAK2-STAT5信号通路促进淋巴细胞的白血病转化。值得注意的是,该项研究利用斑马鱼模型,发现在GATA3的调节下,携带有风险等位基因A的淋巴细胞有更强的迁移能力。

GATA3 rs3824662风险等位基因易感B-ALL的模式图

该研究从临床问题出发锁定疾病易感性位点,通过基础研究明确其易感性机制,发现携带遗传变异风险位点导致T淋巴细胞特异性转录因子GATA3在B淋巴细胞中异常高表达,富集结合在Ph-like特征性基因启动子/增强子区域,打开关闭的染色质位点,重塑了B淋巴细胞染色质空间构象,这种全局性的染色质状态变化通过调节CRLF2信号传导而促使Ph-like ALL的发生。文章充分阐述了转录因子介导的表观基因组重编程,可以直接影响致癌基因的活性,这可能是胚系遗传变异影响癌症发生风险的一个重要机制。

我院杨红波研究员为该文的第一作者。他是黄荷凤院士领衔的复旦大学生殖与发育研究院的骨干成员,专业特长为人类疾病中的3D基因组与表观基因组调控研究,曾在Nature、Nature Genetics、 Molecular Cell等杂志发表多篇一作论文。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1885696, encodeId=f4181885696ee, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Sep 23 09:30:04 CST 2022, time=2022-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342993, encodeId=9ce41342993db, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sun Mar 27 05:30:04 CST 2022, time=2022-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466128, encodeId=b9c4146612838, content=<a href='/topic/show?id=217c292009' target=_blank style='color:#2F92EE;'>#ATA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2920, encryptionId=217c292009, topicName=ATA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387a6772119, createdName=bbjsj_1981, createdTime=Sun Mar 27 05:30:04 CST 2022, time=2022-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620182, encodeId=513e1620182f7, content=<a href='/topic/show?id=258028368d1' target=_blank style='color:#2F92EE;'>#儿童白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28368, encryptionId=258028368d1, topicName=儿童白血病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e75020086705, createdName=xxxx1056, createdTime=Sun Mar 27 05:30:04 CST 2022, time=2022-03-27, status=1, ipAttribution=)]
    2022-09-23 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1885696, encodeId=f4181885696ee, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Sep 23 09:30:04 CST 2022, time=2022-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342993, encodeId=9ce41342993db, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sun Mar 27 05:30:04 CST 2022, time=2022-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466128, encodeId=b9c4146612838, content=<a href='/topic/show?id=217c292009' target=_blank style='color:#2F92EE;'>#ATA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2920, encryptionId=217c292009, topicName=ATA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387a6772119, createdName=bbjsj_1981, createdTime=Sun Mar 27 05:30:04 CST 2022, time=2022-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620182, encodeId=513e1620182f7, content=<a href='/topic/show?id=258028368d1' target=_blank style='color:#2F92EE;'>#儿童白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28368, encryptionId=258028368d1, topicName=儿童白血病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e75020086705, createdName=xxxx1056, createdTime=Sun Mar 27 05:30:04 CST 2022, time=2022-03-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1885696, encodeId=f4181885696ee, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Sep 23 09:30:04 CST 2022, time=2022-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342993, encodeId=9ce41342993db, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sun Mar 27 05:30:04 CST 2022, time=2022-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466128, encodeId=b9c4146612838, content=<a href='/topic/show?id=217c292009' target=_blank style='color:#2F92EE;'>#ATA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2920, encryptionId=217c292009, topicName=ATA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387a6772119, createdName=bbjsj_1981, createdTime=Sun Mar 27 05:30:04 CST 2022, time=2022-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620182, encodeId=513e1620182f7, content=<a href='/topic/show?id=258028368d1' target=_blank style='color:#2F92EE;'>#儿童白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28368, encryptionId=258028368d1, topicName=儿童白血病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e75020086705, createdName=xxxx1056, createdTime=Sun Mar 27 05:30:04 CST 2022, time=2022-03-27, status=1, ipAttribution=)]
    2022-03-27 bbjsj_1981
  4. [GetPortalCommentsPageByObjectIdResponse(id=1885696, encodeId=f4181885696ee, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Sep 23 09:30:04 CST 2022, time=2022-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342993, encodeId=9ce41342993db, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sun Mar 27 05:30:04 CST 2022, time=2022-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466128, encodeId=b9c4146612838, content=<a href='/topic/show?id=217c292009' target=_blank style='color:#2F92EE;'>#ATA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2920, encryptionId=217c292009, topicName=ATA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387a6772119, createdName=bbjsj_1981, createdTime=Sun Mar 27 05:30:04 CST 2022, time=2022-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620182, encodeId=513e1620182f7, content=<a href='/topic/show?id=258028368d1' target=_blank style='color:#2F92EE;'>#儿童白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28368, encryptionId=258028368d1, topicName=儿童白血病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e75020086705, createdName=xxxx1056, createdTime=Sun Mar 27 05:30:04 CST 2022, time=2022-03-27, status=1, ipAttribution=)]

相关资讯

香菜党福音?香菜籽臭是臭了点,但抗癌是真香!

芫荽籽多酚提取物有安全抗白血病潜力!

PNAS:低温大气等离子体(CAP)治疗白血病的“气体”?

表明其可能正是这种共有的“弱点”。此前,研究人员已经能够利用一种气体放电技术——低温大气等离子体(CAP)产生外源性ROS。CAP已被FDA批准为一种导管引导手术刀,用于常规肿瘤和神经外科手术,并在头

“星光奕奕-深度解读”血液大咖云集,邀您赴约!

“星光奕奕-深度解读”第二季线上会议,复星凯特生物科技有限公司专注于细胞免疫治疗,致力于治愈肿瘤患者,届时将邀请血液学界享有盛誉的血液大咖,邀您共赴此次盛会!

JBC:在白血病细胞中靶向致癌酪氨酸磷酸酶SHP2的新型呋喃苯甲酰胺抑制剂的发现

SBI-2130、SBI-4668和相关类似物可能不与催化口袋中的磷酸盐结合环结合。

病例报道:皮肤皮疹最后诊断白血病——N Engl J Med

以为是皮肤病就诊皮肤科,没想到竟是因为白血病!

Nat Nanotech:我国学者开发出高效装载砒霜的仿生递送载体,显著抑制多种白血病

目前,化疗仍然为白血病治疗的重要手段,主要临床用药包括烷化剂、抗代谢类药物、生物碱类药物以及由中国学者提出的砒霜治癌(三氧化二砷,ATO)。